CEO and Board Member at BioAmber, an innovative industrial biotechnology company focused on commercializing a family of renewable chemicals. Restructured executive team, reduced overhead costs, raised $7M in bridge equity financing, refocused commercial strategy and prioritized longer term manufacturing and supply chain cost reductions. Assessed ability to access additional debt financing both with new lenders as well as for existing lenders to extend additional credit. With Board, agreed to ultimately restructure company. Result was a competitive sales process with approximately 100 inquiries and ultimate sale of company.